Verfora will take over the distribution of Boiron products in Switzerland from 1 October 2022

The Boiron range fits seamlessly into the existing complementary medicine portfolio of Verfora and its subsidiary Spagyros, and significantly strengthens its presence in the homeopathy segment.
Boiron products generate sales of around CHF 9 million at retail prices in Switzerland¹⁾.
It is planned that Boiron employees will be transferred to the Verfora organisation.

Both parties are certain that together they will be able to make even better use of each other’s strengths, and that a partnership encompassing a wide range of products from a single source will also offer interesting added value for specialist retailers and patients alike.
Boiron will benefit from Verfora’s broad and established market coverage, particularly in German-speaking Switzerland, while Verfora will gain access to an exciting product portfolio with an innova-tion pipeline and a wide range of training expertise in homeopathy.

Another important reason for the cooperation is the recognition that Boiron and Verfora share the same values and are both interested in a long-term partnership.

¹⁾ IQVIA APO/DRO sell-out CHF MAT April 2022

Media Relations Galenica
Patrick Fehlmann
Business Partner Corporate Communications
Tel. +41 58 852 85 69
E-mail: media@galenica.com

Investor Relations Galenica
Julian Fiessinger
Head of IR & Corporate Finance
Tel. +41 58 852 85 37
E-mail: investors@galenica.com

Media Relations Boiron
Emeline Guiraud-Boisson
Resp. Contenus et Relations médias
Tel. +33 6 77 48 87 70
E-mail: emeline.guiraud-boisson@boiron.fr